Orient Bio

Orient Bio LT Debt/Equity

The Long-Term Debt to Equity Ratio of Orient Bio (002630.KS) as of Oct 29, 2026 is 0.01. In the previous year, Long-Term Debt to Equity Ratio was 0.03 — a change of -50.11% (lower).

LT Debt/Equity

0.01

YoY

-50.11%

Last updated:

Long-Term Debt to Equity Ratio of Orient Bio is 2022 0.01 . Long-Term Debt to Equity Ratio of Orient Bio was 2021 0.03 . It decreases by -50.11% lower compared to the previous year.

The Orient Bio LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
0.21 KRW
Jan 1, 2015
0.15 KRW
Jan 1, 2016
0.13 KRW
Jan 1, 2017
0.15 KRW
Jan 1, 2018
0.23 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.03 KRW
Jan 1, 2022
0.01 KRW
The Orient Bio LT Debt/Equity history
YEARLT Debt/EquityYoY
0.01-50.11%
0.03+3,826.52%
0.00-99.67%
0.23+56.51%
0.15+12.70%
0.13-14.48%
0.15-27.87%
0.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Long-Term Debt to Equity Ratio of Orient Bio is 0.01 in 2022.

Long-Term Debt to Equity Ratio of Orient Bio changed from 0.03 to 0.01, representing a -50.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Orient Bio since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Orient Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Orient Bio

All Key Metrics — Orient Bio